

## **Pharmacy Grand Rounds**

200 First Street SW Rochester, Minnesota 55905 https://ce.mayo.edu/pharmacy-grandrounds-2024

# A Rare and BILE Situation: Management Strategies for Primary Biliary Cholangitis

Session Date: 08/20/2024

**Session Time:** 11:00 – 11:45 AM (CST)

## **Target Audience**

This continuing education (CE) session was planned to meet the needs of professional staff who deal with the selection and monitoring of medication(s) as part of their patient care duties, including pharmacists, RNs, APRNs, PAs, MDs.

### **Activity Overview**

Primary biliary cholangitis (PBC) is a chronic, inflammatory, and progressive autoimmune disease that, if left untreated, can lead to cirrhosis and liver failure, resulting in liver-related mortality. Since its initial approval in 1997, ursodeoxycholic acid (UDCA) has been established as the standard of care for PBC, effectively enabling patients to achieve survival rates comparable to those without PBC. However, up to 40% of patients do not respond adequately to UDCA, creating a need for additional pharmacologic therapies for PBC. In recent years, effective second-line treatment options, including obeticholic acid and fibrates have been integrated into contemporary PBC management protocols and ongoing research has introduced several promising new therapies with distinct mechanisms of action, enriching the therapeutic landscape for PBC. This presentation will critically examine the current literature on PBC management, emphasizing the evaluation of recently approved therapies and comparing their efficacy profiles.

## **Learning Objectives**

At the conclusion of this knowledge-based CE session, participants should be able to:

- 1. Describe the pathophysiology and pharmacologic treatment goals for primary biliary cholangitis (PBC).
- 2. Outline a treatment algorithm for contemporary pharmacologic management of PBC based on current literature.
- 3. Define the role of emerging pharmacologic therapies in the treatment of PBC.

## **Faculty Information**

Megan Edwards, PharmD PGY2 Internal Medicine Pharmacy Resident Mayo Clinic Hospital - Rochester, MN

Megan Edwards received a Doctor of Pharmacy degree from the University of Nebraska Medical Center College of Pharmacy. She completed a PGY1 pharmacy residency at Mayo Clinic Hospital – Rochester and is a current PGY2 internal medicine pharmacy resident at Mayo Clinic Hospital – Rochester. Her practice interests include infectious diseases, cardiology, and nutrition.



## **Approved Provider Statement**



In support of improving patient care, this activity is planned and implemented by Mayo Clinic College of Medicine and Science. Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

#### **Credit Statements**

#### **AMA**

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### **ACPE**



**ACPE Universal Activity Number (UAN):** JA0000238-0000-24-004-L01-P Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 0.75 ACPE Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity

#### **ANCC**

Mayo Clinic College of Medicine and Science designates this activity for a maximum of 0.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

#### AAPA



Mayo Clinic College of Medicine and Science has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

## **Educational Format and CE Requirements**

This CE session is available as a live presentation, including live webcast. Participants must complete the following to record attendance and obtain CE credit:

- 1. Attend the entire session.
- 2. Text the session code to 507-200-3010 within 48 hours of the live presentation to record attendance.
  - a. This number is only used for receiving text messages related to tracking attendance
  - b. Employees are encouraged to create a contact in their mobile phone, as the same number is used to record attendance for every session
- 3. Complete the online evaluation for the respective session within 2 weeks of live presentation.

Pharmacist CE credit is electronically transferred to the National Association of Boards of Pharmacy CPE Monitor. To track CE, please go to NABP CPE Monitor.

Non-pharmacist attendees can print out a record of attendance at ce.mayo.edu after completing the evaluation and claiming credit.

Live Webcast - access during presentation times

## **Disclosure Summary**

As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. All who are in a position to control the content are required to disclose all financial relationships with any ineligible company. Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

- Megan Edwards, PharmD
  - o Declares no financial relationship(s) pertinent to this session
  - o Declares off-label use of medications will be discussed during this presentation
    - Fenofibrate
    - Bezafibrate
    - Seladelpar
    - Saroglitazar
    - Setanaxib
    - Tropifexor

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session. Members include:

- Jennifer Elmer, DNP, APRN, CCNS
- Andrew Herber, PA-C
- Sarah Jane Kotval, BSW, RSS Coordinator
- Scott Nei, PharmD, BCPS, BCCCP, FCCM, FMSHP
- Wayne Nicholson, MD, PharmD, BCPS
- Sara Thompson, PharmD, MEd, BCACP

All relevant financial relationships have been mitigated.

For additional disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee members visit ce.mayo.edu, About Us, Disclosures - or - https://ce.mayo.edu/content/disclosures

## System and Technical Requirements

For participants viewing the webcast, sessions are delivered via Mayo Clinic intranet web browser and Adobe® PDF. For participants viewing outside the Mayo Clinic firewall, a VPN connection is required for remote access. Recommended web browser includes Google Chrome. This session is planned and coordinated by **the Department of Pharmacy, Mayo Clinic.**